Interpretation on Cancer Statistics, 2024 and Comparison of Cancer Prevalence Between China and America

ZHAO Wenjing; YIN Zhouyi; WANG Yuxin; LI Wenqing

doi:10.3971/j.issn.1000-8578.2024.24.0322

Cancer Research on Prevention and Treatment > 2024 > 51(8): 630-641. > DOI: 10.3971/j.issn.1000-8578.2024.24.0322

ZHAO Wenjing, YIN Zhouyi, WANG Yuxin, LI Wenqing. Interpretation on Cancer Statistics, 2024 and Comparison of Cancer Prevalence Between China and America[J]. Cancer Research on Prevention and Treatment, 2024, 51(8): 630-641. DOI: 10.3971/j.issn.1000-8578.2024.24.0322

Citation:

PDF (3535 KB)

Interpretation on Cancer Statistics, 2024 and Comparison of Cancer Prevalence Between China and America

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Funding: National Natural Science Foundation of China (No. 82273704)

More Information

Corresponding author:
LI Wenqing, E-mail: wenqing_li@bjmu.edu.cn
Received Date: April 10, 2024
Revised Date: May 06, 2024
Accepted Date: June 05, 2024

Graphical Abstract

Abstract

Abstract

In January 2024, Cancer Statistics, 2024 was published in CA: A Cancer Journal for Clinicians. This report estimated cancer cases and deaths in 2024 and described the secular trends of major cancers over recent decades. We summarized the report and integrated the latest data on the cancer burden in China to compare the prevalence cancer between two countries. We also comprehensively interpreted the underlying reasons for these trends to provide insights for cancer prevention and control strategies in China.
- Cancer,
- Morbidity,
- Mortality,
- Burden,
- Trend

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (41)

References

[1]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. doi: 10.3322/caac.21820
[2]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. doi: 10.3322/caac.21763
[3]	Silverberg E, Grant RN. Cancer statistics, 1970[J]. CA Cancer J Clin, 1970, 20(1): 11-23.
[4]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
[5]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. doi: 10.3322/caac.21654
[6]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[7]	Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER Research Data, 8 Registries, November 2022 Submission (1975–2020)-Linked To County Attributes-Time Dependent (1990–2021) Income/Rurality, 1969–2021 Counties[J]. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, 2023.
[8]	Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data—Cancer in North America Research Data, 2016–2020, Delay Adjusted Factors—American Cancer Society Facts and Figures (which includes data from the Centers for Disease Control and Prevention’s National Program of Cancer Registries, the Canadian Cancer Registry’s Provincial and Territorial Registries, and the National Cancer Institute’s SEER Registries, certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods)[J]. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, 2023.
[9]	Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data—Cancer in North America Research Data, 1998–2020, Delay Adjusted Factors—American Cancer Society Facts and Figures (which includes data from the Centers for Disease Control and Prevention’s National Program of Cancer Registries, the Canadian Cancer Registry’s Provincial and Territorial Registries, and the National Cancer Institute’s SEER Registries, certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods)[J]. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, 2023.
[10]	Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data—Cancer in North America Research Data, 1995–2020, with Race/Ethnicity, Standard File, American Cancer Society Facts and Figures (which includes data from the Centers for Disease Control and Prevention’s National Program of Cancer Registries, the Canadian Cancer Registry’s Provincial and Territorial Registries, and the National Cancer Institute’s SEER Registries, certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods)[J]. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, 2023.
[11]	Percy C, van Holten V, Muir C. International classification of diseases for oncology[M]. 2^nd edition. Geneva: World Health Organization, 1990.
[12]	Steliarova-Foucher E, Stiller C, Lacour B, et al. International Classification of Childhood Cancer, third edition[J]. Cancer, 2005, 103(7): 1457-1467. doi: 10.1002/cncr.20910
[13]	Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study[J]. Lancet Oncol, 2017, 18(6): 719-731. doi: 10.1016/S1470-2045(17)30186-9
[14]	Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey[J]. Biol Psychiatry, 2011, 69(6): 592-600. doi: 10.1016/j.biopsych.2010.10.023
[15]	Mcguire V, Lichtensztajn DY, Tao L, et al. Variation in patterns of second primary malignancies across U. S. race and ethnicity groups: a Surveillance, Epidemiology, and End Results (SEER) analysis[J]. Cancer Causes Control, 2024, 35(5): 799-815. doi: 10.1007/s10552-023-01836-2
[16]	刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13. [Liu ZC, Li ZX, Zhang Y, et al. Interpretation on the report of Global Statistics 2020[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2021, 7(2): 1-13.] Liu ZC, Li ZX, Zhang Y, et al. Interpretation on the report of Global Statistics 2020[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2021, 7(2): 1-13.
[17]	Liu S, Wu X, Lopez AD, et al. An integrated national mortality surveillance system for death registration and mortality surveillance, China[J]. Bull World Health Organ, 2016, 94(1): 46-57. doi: 10.2471/BLT.15.153148
[18]	GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1736-1788. doi: 10.1016/S0140-6736(18)32203-7
[19]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc.2024.01.006
[20]	Qi J, Li M, Wang L, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8(12): e943-e955. doi: 10.1016/S2468-2667(23)00211-6
[21]	Chen R, Aschmann HE, Chen YH, et al. Racial and Ethnic Disparities in Estimated Excess Mortality From External Causes in the US, March to December 2020[J]. JAMA Intern Med, 2022, 182(7): 776-778. doi: 10.1001/jamainternmed.2022.1461
[22]	Green J, Cairns BJ, Casabonne D, et al. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk[J]. Lancet Oncol, 2011, 12(8): 785-794. doi: 10.1016/S1470-2045(11)70154-1
[23]	Klein SL, Flanagan KL. Sex differences in immune responses[J]. Nat Rev Immunol, 2016, 16(10): 626-638. doi: 10.1038/nri.2016.90
[24]	Jackson SS, Marks MA, Katki HA, et al. Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors[J]. Cancer, 2022, 128(19): 3531-3540. doi: 10.1002/cncr.34390
[25]	Siegel RL, Torre LA, Soerjomataram I, et al. Global patterns and trends in colorectal cancer incidence in young adults[J]. Gut, 2019, 68(12): 2179-2185. doi: 10.1136/gutjnl-2019-319511
[26]	Forjaz G, Ries L, Devasia TP, et al. Long-term Cancer Survival Trends by Updated Summary Stage[J]. Cancer Epidemiol Biomarkers Prev, 2023, 32(11): 1508-1517. doi: 10.1158/1055-9965.EPI-23-0589
[27]	Xu X, Chen L, Nunez-Smith M, et al. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries[J]. J Natl Cancer Inst, 2023, 115(6): 636-643. doi: 10.1093/jnci/djad027
[28]	胡志强, 游伟程, 潘凯枫, 等. 中、美两国癌症流行特征分析——《2023美国癌症统计报告》解读[J]. 科技导报, 2023, 41(18): 18-28. [Hu ZQ, You WC, Pan KF, et al. Epidemiological characteristics of cancers in China and American: Interpretation of the report of American cancer statistics, 2023[J]. Ke Ji Dao Bao, 2023, 41(18): 18-28.] Hu ZQ, You WC, Pan KF, et al. Epidemiological characteristics of cancers in China and American: Interpretation of the report of American cancer statistics, 2023[J]. Ke Ji Dao Bao, 2023, 41(18): 18-28.
[29]	Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1
[30]	Qi J, Wang L, Zhou M, et al. Mortality of Common Gastrointestinal Tract Cancers - Huai River Basin, 2008-2018[J]. China CDC Wkly, 2020, 2(16): 259-264.
[31]	Zhang M, Zhong Y, Zhao Z, et al. Cervical Cancer Screening Rates Among Chinese Women - China, 2015[J]. China CDC Wkly, 2020, 2(26): 481-486. doi: 10.46234/ccdcw2020.128
[32]	Zhang M, Zhong Y, Bao H, et al. Breast Cancer Screening Rates Among Women Aged 20 Years and Above - China, 2015[J]. China CDC Wkly, 2021, 3(13): 267-273. doi: 10.46234/ccdcw2021.078
[33]	Fan X, Qin X, Zhang Y, et al. Screening for gastric cancer in China: Advances, challenges and visions[J]. Chin J Cancer Res, 2021, 33(2): 168-180. doi: 10.21147/j.issn.1000-9604.2021.02.05
[34]	Liu F, Guo F, Zhou Y, et al. The Anyang Esophageal Cancer Cohort Study: study design, implementation of fieldwork, and use of computer-aided survey system[J]. PLoS One, 2012, 7(2): e31602. doi: 10.1371/journal.pone.0031602
[35]	Chen R, Liu Y, Song G, et al. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study[J]. Gut, 2021, 70(2): 251-260.
[36]	Wei WQ, Chen ZF, He YT, et al. Long-Term Follow-Up of a Community Assignment, One-Time Endoscopic Screening Study of Esophageal Cancer in China[J]. J Clin Oncol, 2015, 33(17): 1951-1957. doi: 10.1200/JCO.2014.58.0423
[37]	Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030[J]. Chin J Cancer Res, 2018, 30(6): 571-579. doi: 10.21147/j.issn.1000-9604.2018.06.01
[38]	Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun (Lond), 2021, 41(10): 1037-1048. doi: 10.1002/cac2.12197
[39]	Lu L, Mullins CS, Schafmayer C, et al. A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors[J]. Cancer Commun (Lond), 2021, 41(11): 1137-1151. doi: 10.1002/cac2.12220
[40]	尹周一, 王梦圆, 游伟程, 等. 2022美国癌症统计报告解读及中美癌症流行情况对比[J]. 肿瘤综合治疗电子杂志, 2022, 8(2): 54-63. [Yin ZY, Wang MY, You WC, et al. Interpretation on the report of American cancer statitics, 2022 and comparison of cancer prevalence in China and America[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2022, 8(2): 54-63.] Yin ZY, Wang MY, You WC, et al. Interpretation on the report of American cancer statitics, 2022 and comparison of cancer prevalence in China and America[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2022, 8(2): 54-63.
[41]	Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study[J]. Lancet Oncol, 2012, 13(8): 790-801. doi: 10.1016/S1470-2045(12)70211-5

Cited By

Cited by

Periodical cited type(4)

1.	肖珊珊，陈红涛，何素素，黄佳倩，李雯，邓堋，宋小花. 恐惧疾病进展在乳腺癌患者压力知觉与抑郁间的中介效应. 中国健康心理学杂志. 2025(03): 454-459 .
2.	杨淞，宗立国，田杰，孟丽. DRGs背景下某三级甲等综合性医院住院恶性肿瘤死亡病例分析. 山东医药. 2025(02): 75-79 .
3.	于静舟，吕晓静，孙亚琳，任帅，王中秋. CT影像组学模型评估直肠癌周围神经或脉管侵犯的价值. 现代肿瘤医学. 2024(19): 3738-3743 .
4.	蔡柳，熊宏泰，韩欣璞，于惠博，王成磊，郑红刚. 基于“肝为气化之始”探讨恶性肿瘤与情志关系. 山东中医杂志. 2024(11): 1203-1207+1218 .

Other cited types(0)

Figures(6) / Tables(2)

Get Citation

PDF

XML

Article views (3460) PDF downloads (4719) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Interpretation on Cancer Statistics, 2024 and Comparison of Cancer Prevalence Between China and America